

## ARTICLE

# Serotonin syndrome: a spectrum of toxicity

Rabia Ellahi

**Rabia Ellahi** is an ST6 in general adult psychiatry at Ailsa Hospital, Ayr, Scotland.

**Correspondence** Dr Rabia Ellahi, Ailsa Hospital, Ayr KA6 6AB, UK. Email: rellahi1@nhs.net

## SUMMARY

Serotonin syndrome (serotonin toxicity or serotonin toxidrome) is a potentially serious and theoretically predictable reaction that appears to be rarely diagnosed in practice in the UK. Some symptoms of serotonin syndrome overlap with features of other presentations in psychiatry and thus may be misattributed to mental illness ('diagnostic overshadowing'). Further, there may be diagnostic dilemmas in patients on combinations of drugs, those receiving drugs with previously unknown serotonergic properties or where there are drug interactions. Prescriber vigilance and holistic review of the patient, including the pharmacotherapy, may be helpful in avoiding progression of serotonin syndrome to more serious outcomes.

## LEARNING OBJECTIVES

- Raised awareness of serotonin syndrome, its clinical presentation and diagnostic criteria
- Recognise multiple pathways that may contribute to the development of serotonin syndrome, with particular emphasis on the importance of the cytochrome P450 enzyme system
- Increased understanding of the importance of early management in preventing progression to more toxic states

## DECLARATION OF INTEREST

None

varying degrees of severity. Less severe presentations of the syndrome may remain undiagnosed, with symptoms such as anxiety, confusion, restlessness, headache, insomnia, agitation and hypomanic behaviour perhaps being attributed to the mental illness under treatment or misdiagnosed.

## Serotonin syndrome: a brief history

One of the earliest descriptions of the syndrome emanates from 1955 and is that of a 60-year-old physician with pulmonary tuberculosis treated with iproniazid; after receiving 100 mg of pethidine he displayed symptoms of acute onset consistent with serotonin toxicity (Shee 1960). Several other reports followed, but another 5 years elapsed before the development of the hypothesis that these symptoms resulted from excess serotonin. It was much later, in the early 1980s, that the syndrome was set in its modern day context. An animal model of serotonin syndrome, with some differences, has also been described and generally confirms the role of 5-HT<sub>2A</sub> receptors in the development of raised temperature and rigidity (Jacobs 1974).

Sternbach (1991), after closer analysis of 12 out of 38 published cases of symptoms in humans, defined this condition as 'serotonin syndrome'. However, he concluded that:

'Further work is needed to establish the diagnostic criteria, incidence, and predisposing factors, to identify the role of 5-HT antagonists in treatment, and to differentiate the syndrome from neuroleptic malignant syndrome'.

Sternbach's criteria (Box 1) suggested that, in the presence of a known serotonergic agent, three or more out of ten symptoms should be present to merit the diagnosis, that alternative possible causes be excluded and that no recent increase or addition of a psychotropic agent has occurred. These criteria have not been specifically validated, and indeed controversy continues regarding the wording of the requirements, not least from the point of fulfilling even the first criterion, i.e. the precise definition of 'a known serotonergic agent'.

Hegerl *et al* (1998) subsequently modified Sternbach's criteria on the basis of the observed correlation between adverse effects and paroxetine dose, and developed the Serotonin Syndrome

Serotonin syndrome, variously described as serotonin toxicity or serotonin toxidrome, is often an iatrogenic adverse drug reaction. In this article serotonin syndrome refers to the broad spectrum of clinical presentations in humans secondary to a relative or absolute increase in serotonin levels in the central and peripheral nervous system.

A study based in general practice reported the incidence of serotonin syndrome at 0.5–0.9 cases per 1000 patient-months of treatment. This is likely to be an underestimate as it pertains to patients on monotherapy with selective serotonin reuptake inhibitors (SSRIs); this rises to 15% where overdose with serotonergic medication has occurred (Isbister 2007). Serotonin syndrome can present as a spectrum of different symptoms and signs and in

### BOX 1 Sternbach's criteria for serotonin syndrome

Sternbach's criteria stipulate that three conditions must be met:

- 1 there should have been a recent addition or increase in a 'known' serotonergic agent
- 2 there should not have been a recent addition or increase in a 'neuroleptic' (antipsychotic) agent
- 3 possible alternative causes such as infection, substance misuse or withdrawal and metabolic upset should be excluded.

In addition, three or more of the ten symptoms listed below must be present:

- Mental status changes
- Pyrexia
- Myoclonus
- Hyperreflexia
- Incoordination
- Agitation
- Diaphoresis
- Tremor
- Shivering
- Diarrhoea

(Adapted from Sternbach 1991)

Scale, which they described as a scale 'for the operationalized assessment of both the presence and the severity of the core symptoms of the serotonin syndrome'.

Radomski *et al* (1999), following the detailed review of a further 24 cases reported in the medical literature from 1991 to 1995, proposed a severity-based classification for serotonin syndrome into mild, full-blown and toxic states.

The Hunter Serotonin Toxicity Criteria (HSTC) (Dunkley 2003) were based on an Australian study of 473 patients who had taken an overdose of SSRIs and had been referred to the Hunter Area Toxicology Service between 1987 and 2002. The authors concluded that the presence of at least five symptoms was sufficient for a clinical toxicologist to diagnose serotonin toxicity. The authors' observation of associated pyrexia and hypertonicity among the more severe cases led to an algorithm combining seven features (Box 2). The HSTC are said to be the most sensitive, specific and easy-to-use decision rules currently available for serotonin syndrome (Haddad 2008; Monte 2010).

### Serotonin

Serotonin, or 5-hydroxytryptamine (5-HT,  $C_{10}H_{12}N_2O$ ), is a monoamine neurotransmitter

derived from dietary tryptophan. Serotonin was discovered in 1948 and it received its name from its apparent property of being a vasoconstriction-inducing constituent of serum. Serotonin has a role in many body processes, including the regulation of mood and other emotional behaviours as well as pain perception, aggression, vomiting, the sleep cycle, appetite, haemostasis, sexual function and body temperature control.

The serotonin receptor and its many subtypes is the most prolific of all neuroreceptors in the human body. At least seven families of serotonin receptor (5-HT<sub>1-7</sub>) have been identified, most of which have several further subtypes. Serotonin does not cross the blood–brain barrier and only about 1 mg of serotonin is produced in the central nervous system (CNS). Metabolism proceeds mainly in the liver via monoamine oxidase enzymes; the main end product, 5-hydroxyindoleacetic acid (5-HIAA), is excreted via the kidneys.

Predominantly used in the treatment of depression, SSRIs are also used to treat seemingly diverse conditions such as eating disorders, neuropathic pain, sexual behaviour, sleep, aggression and anxiety disorders (Lee 2010). An interplay of over- and underactivity of various 5-HT receptor subtypes, including 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub>, as well as other neurotransmitter systems, notably the noradrenergic and glutamatergic, are thought to be involved (Monte 2010).

### Serotonin syndrome and the role of cytochrome P450 enzymes

Many drugs, including SSRIs, can precipitate serotonin syndrome either directly or indirectly via their action on the cytochrome P450 (CYP) enzyme system (Box 3). CYP is a large family of oxidative enzymes located in the endoplasmic

### BOX 2 The Hunter Serotonin Toxicity Criteria

Requirement – in the presence of a serotonergic agent:

- 1 clonus (inducible, spontaneous or ocular) is the cardinal sign
- 2 agitation
- 3 diaphoresis
- 4 tremor
- 5 hyperreflexia
- 6 rigidity
- 7 body temperature greater than 38°C

Items 6 and 7 were derived from their frequent presence in severe and toxic serotonin syndrome

(Adapted from Dunkley 2003)

**BOX 3 Drugs associated with serotonin toxicity, by mode of action**

<p><b>Precursors of excess serotonin or serotonin agonists</b>                  Buspirone, L-tryptophan, L-dopa, trazodone</p> <p><b>Reduced reuptake of serotonin</b>                  Tricyclic antidepressants, especially clomipramine, imipramine                  Amphetamines, cocaine                  Serotonin–noradrenaline reuptake inhibitors (SNRIs), especially venlafaxine                  Selective serotonin reuptake inhibitors (SSRIs)                  Trazodone                  St John’s wort, tramadol</p> <p><b>Reduced breakdown of serotonin</b>                  Monoamine oxidase inhibitors (MAOIs):                  reversible: moclobemide</p>	<p>irreversible: tranylcypromine, phenelzine                  Linezolid, selegiline, St John’s wort</p> <p><b>Drugs that increase the release of serotonin</b>                  Amphetamine, cocaine, fenfluramine, methamphetamine, 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy), methylphenidate, pethidine, reserpine, tramadol</p> <p><b>Others</b>                  Buspirone, carbamazepine, lithium, methylene blue                  Phenylpiperidine opioids: dextromethorphan, fentanyl, methadone, pethidine, tramadol                  Novel psychoactive substances</p>
---	---

(Adapted from Haddad 2008; Buckley 2014)

reticulum of cells. The highest densities of these enzymes occur in the liver, but they are also found in the small intestine wall, kidneys, placenta, brain and lungs. The importance of the CYP enzyme system lies in its role not only in the production, but also in the breakdown, of steroids, cholesterol, vitamins and prostacyclins, and in the metabolism of food and medications – notably antidepressants, opioids and antipsychotics, among others.

Over 50 CYP enzymes are known. Of these, only half a dozen appear to be involved in the metabolism of 90% of drugs. Each CYP is encoded by a particular gene, one half of the gene pair originating from each of the biological parents. The pattern of inheritance and gene expression, deletion or aberration results in genetically based inter-individual and interracial variations in the effective activity of CYP isoenzymes. This genetic polymorphism is hypothesised to be one of the key mechanisms accounting for a range of drug effects.

Around one in ten ‘Caucasians’ (White/European people) is thought to have reduced activity of the CYP2D6 isoenzymes (Park 2014), which alone are thought to be involved in the metabolism of 25% of marketed drugs, including antidepressants, antipsychotics, opioids, antiemetics and antiarrhythmics (Zhou 2009). The required therapeutic dose of half of the antidepressants in use is believed to be closely related to the individual’s CYP2D6 genotype; non-response has been suggested to result from possessing multiple copies of the CYP2D6 coding gene. A drug or substrate may be metabolised by more than one CYP isoenzyme (Park 2014). Different

CYP enzymes may be involved in the metabolism of the prodrug, the parent compound or the (active) metabolites of the drug (Lynch 2007). Additional considerations include genetic polymorphisms of the neurotransmitter transporters and of their receptors.

**Serotonin syndrome and foods**

*Grapefruit juice*

Grapefruit juice is of particular relevance, as many medications may be taken with it at breakfast. Grapefruit, and at lower concentration essential citrus oils, contain bergamottin, a furanocoumarin. Furanocoumarins are a group of plant-produced chemicals that are toxic to insects and/or fungi. Bergamottin has a prominent inhibitory effect on intestinal CYP3A4 enzyme. CYP3A4 constitutes 70% of the CYP present in the epithelial cells of the small intestine and 30% of the CYP present in the liver. A single glass of grapefruit juice (200 ml), reduces the activity of intestinal CYP3A4 by up to a half within 4 h. Further, this inhibitory effect continues into the next day, with almost a third of the reduced activity still evident; it can take up to 3 days to subside.

It has been suggested that grapefruit juice also inhibits an intestinal P-glycoprotein pump which transports many of the CYP3A4 substrates, notably drugs, from the enterocytes back into the gut lumen. This results in reduced first-pass metabolism and, consequently, increased bioavailability of several drugs. Sertraline is predominantly metabolised by CYP3A4, and a 50% increase in bioavailability has been reported when it is consumed along with grapefruit juice; the degree of inhibition, however, is subject to inter-individual variability (Lee 1999). Where there is liver damage, for instance in alcohol misuse, there is an added reduction in the hepatocyte CYP contribution; this effect may then become even more pronounced (Kiani 2007).

*Caffeine*

Caffeine is a ubiquitous constituent of many foods and drinks and its consumption is often higher in people with mental illnesses. Caffeine affects the release of catecholamines, and is known to improve mood, but it may worsen psychosis. Some people with depression may also be more sensitive to the effects of caffeine, and experience a worsening of anxiety and agitation (Cauli 2005).

Caffeine is mainly metabolised via CYP1A2; fluvoxamine, which is a potent inhibitor of this enzyme, can reduce caffeine clearance by up to 80% and potentially precipitate caffeine toxicity. Caffeine itself can also inhibit CYP1A2;

theoretically, it may increase available levels of other, serotonergic, drugs metabolised by CYP1A2, notably tricyclic antidepressants (Gillman 2010a). Herraiz & Chapparo (2006) state that the constituents of prepared coffee demonstrate (reversible) inhibitory effects on both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) both of these enzymes in the mitochondrial outer membrane are crucial in the oxidative catabolism of various neurotransmitters, the former being more specifically involved in the inactivation of serotonin. Consumption of large amounts of caffeine in tandem with the ingestion of serotonergic medications, particularly antidepressants, may contribute to the development of serotonin syndrome in susceptible patients (Shioda 2004).

### Others

Other important CYP enzyme interactions with serotonergic medications include St John's wort (*Hypericum perforatum*), which inhibits CYP3A4 and also contains constituents inhibiting several other enzymes (CYP1A2, 2C9, 2C19, 2D6), cigarette smoke (CYP1A2) and alcohol, especially red wine (CYP2E1). Some of these substances interact with each other; for example, cigarette smoke induces metabolism of caffeine (Zhou 2004).

### Presentation

Patients in mental health services are often treated with combinations of antidepressants and antipsychotics; the antagonistic role of olanzapine and risperidone at 5-HT<sub>2A</sub> receptors and the partial agonism of many atypical antipsychotics at 5-HT<sub>1A</sub> receptors is often disregarded. Further, it has been suggested that some people with psychiatric illness, especially those with schizophrenia, have abnormal thermoregulation, which includes an elevated baseline temperature (Chang 2004). In susceptible individuals, serotonin syndrome may be precipitated when serotonin levels at specific synapses in the CNS are multiplied manifold.

In practice, serotonin syndrome usually results from drug interactions, classically secondary to the combined overdose of an SSRI with an (irreversible) monoamine oxidase inhibitor (MAOI), which in around 50% of cases is believed to result in severe serotonin syndrome. Moderate serotonin toxicity has been noted in 15% of people who took large quantities of SSRIs in overdoses (Buckley 2014). It can also occur where the drugs used have previously unrecognised serotonergic properties. Among others, anticonvulsants, anti-emetics, antimicrobials, anti-migraine and recreational drugs have been associated with

serotonin syndrome (Gillman 2010b; Monte 2010; Cooper 2013).

Severe serotonin toxicity can have a rapid onset and deterioration; death can ensue within 24 h. This may be alarming not only for the observer but also for the patient, who often remains alert in the early stages (Gillman 2005). Symptoms may be noted from 2 h and most present within 6–8 h of addition/ingestion of the relevant substance (Ener 2003; Haddad 2008). Chronic, less dramatic presentations have been described where the only symptom is anxiety, restlessness or diarrhoea, thus perhaps escaping recognition. In some cases symptoms may be misattributed to deterioration in mental state, with the risk of increasing or additional medication (Ener 2003).

### Serotonin syndrome: mechanism

Presynaptic neurons in the raphe nuclei, largely restricted to the basal plate of the pons and medulla, synthesise and release serotonin. The serotonin transporter (SERT) located on these cells plays a major role in reabsorption of much of this; some of this intrasynaptic serotonin also binds to autoreceptors, triggering a negative feedback loop, thus modulating its own release. Serotonergic medications through different mechanisms act on various steps of this process: SSRIs block the action of SERT, thereby increasing the available serotonin in the synaptic space by limiting the recycling process. Increased serotonin neurotransmission results, mainly at postsynaptic 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors; currently both these subtypes, as well as peripheral and central serotonin, are implicated in the wide range of symptoms and signs in serotonin syndrome (Haddad 2008).

There appears to be a sequential stimulatory effect in the presence of excess serotonin, which corresponds roughly to the spectrum of increasing toxicity. This may be observed clinically when the more abundant 5-HT<sub>1A</sub> receptors are stimulated at lower levels, accounting for some of the less severe symptoms, including, initially, hypothermia. Overstimulation of 5-HT<sub>2A</sub> receptors occurs at much higher serotonin concentrations; this subtype is now generally considered to be the mediator of the more severe, toxic aspects of serotonin syndrome, with marked pyrexia and neuromuscular hyperactivity. Not only is there a complex interplay between these two receptors, but also very high serotonin levels potentiate glutamatergic, noradrenergic and dopaminergic pathways, with progression to extreme toxic states; such toxicity may be precipitated subsequent to the ingestion of

cocaine or 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) (Haddad 2008).

There is support for the theory that a particular concentration of serotonin is a prerequisite for the development of serotonin syndrome. However, there is considerable inter-individual variation and this variability has its basis in genetic factors, which include polymorphisms of *CYP2D6*, *SERT* or the serotonin receptors themselves (Gillman 2005; Fox 2007).

### Diagnosis

Diagnosis is clinical and associated with a history of current or recent ingestion of a serotonergic drug(s). Measurement of serum serotonin levels does not add to the diagnosis; psychotropic drugs can accumulate in the brain in concentrations that are 10–40 times higher than in the serum. Acute medical presentations with generalised clonus (usually easier to elicit in the lower limbs) associated with rising temperature should prompt careful scrutiny of the pharmacotherapy and the consumption of certain foods and supplements, such as caffeine in its various forms, grapefruit juice and over-the-counter medicines such as St John's wort. Other possible causes should be excluded.

- a. The term ocular clonus covers abnormal involuntary ocular movements of varying degrees and direction; if present, it is considered to be a cardinal sign in serotonin syndrome.
- b. Hypomania is a recognised consequence of the use of SSRIs for depression in some patients.
- c. Xenobiotics are chemicals or compounds that are either foreign to or present in unusually large quantities in a biological system.

Serotonin syndrome should be considered when any patient presents with a combination of suggestive clinical features. In practice it can be difficult to identify clonus and hyperreflexia in severely toxic cases with progression to rigidity.

It may be simpler to consider the symptoms under three group headings:

- neuromuscular: tremor, ocular clonus,<sup>a</sup> myoclonus, hyperreflexia, akathisia and muscular rigidity
- autonomic: fever, flushed skin, tachycardia, diaphoresis, diarrhoea, abdominal cramps and tachypnoea
- mental state/CNS: agitation, insomnia, hypomania,<sup>b</sup> hallucinations (visual), confusion and seizures.

### Differential diagnosis

Before diagnosing serotonin toxicity it is important to consider neuroleptic (antipsychotic) malignant syndrome (Table 1) and other alternative or even comorbid possible causes, such as infection, metabolic upset and substance misuse/withdrawal states. Additional factors that may contribute to serotonin syndrome include dietary supplements, lithium ingestion, electroconvulsive therapy (ECT), hepatic or renal diseases, genetic defects in xenobiotic<sup>c</sup> metabolising enzymes, and combinations of psychotropic medication with inhibitors of their enzymes, for example an SSRI with an MAOI.

#### What to look for

Higher risk of serotonin syndrome is associated with increasing age, increasing dose of serotonergic agents and serotonergic agents in combination with medications that have high *CYP2D6* inhibitory function. It is important to exercise greater vigilance where patients present with comorbid depressive symptoms and chronic pain. Commonly prescribed medications, such as antidepressants with tramadol, may interact, and at higher doses, tramadol is reported as being able to both block reuptake and induce release of serotonin (Park 2014). A higher incidence of serotonin syndrome has been reported in patients who are undergoing haemodialysis for end-stage renal disease and who are taking SSRIs; this may be due to decreased renal function (Chander 2011). Although rare, transient serotonin syndrome has been reported following a single dose of ECT in at least one patient receiving paroxetine. One of the mechanisms proposed was that ECT had increased the permeability of the blood–brain barrier, thus facilitating accumulation of more toxic levels of the SSRI in the brain (Okamoto 2012). Morrish

**TABLE 1** Comparison of clinical features of serotonin syndrome with those of neuroleptic malignant syndrome

Clinical features	Serotonin syndrome	Neuroleptic malignant syndrome
Differentiating features	Predictable adverse reaction Serotonergic hyperfunction Rapid onset, within 2–4 h (most within 24 h), with rapid deterioration in severe cases Rapid resolution Restlessness Clonus Shivering Hyperreflexia	Idiosyncratic adverse reaction Dopaminergic hypofunction Slower onset, over 5–7 days Symptoms may fluctuate Slower resolution Increased muscle tone Bradykinesia More common in men than in women May be history of exhaustion, dehydration, etc. before onset
Early features	Anxiety Restlessness Tremor (hypothermia, then pyrexia) Increased borborygmi Diarrhoea Tachycardia Raised creatine kinase level	Hypersalivation Diaphoresis Incontinence Low-grade temperature rise to >38°C Tremor Bradykinesia Tachycardia Markedly raised creatine kinase level
Later (more severe) features	Clonus Labile blood pressure Marked pyrexia Truncal rigidity Respiratory distress Seizures Multi-organ failure	Labile blood pressure Marked pyrexia Dysphagia Mutism Catatonic features Lead-pipe rigidity Altered consciousness

Sources: Ahuja 2009; Odagaki 2009; Steele 2011; Park 2014.

(2014) describes presentations with fever, rigidity and confusion in patients with Parkinson's disease treated with MAO-B inhibitors who were also being treated for depression.

### *Serotonin syndrome and non-prescribed drugs*

The first-generation antihistamine chlorphenamine is thought to display serotonin reuptake inhibiting activity when ingested with dextromethorphan, such as in overdose of over-the-counter cough medicines (Monte 2010). Recreational drugs, prominently MDMA/ecstasy, in creative combinations with amphetamines, cocaine and variously obtained other drugs, such as attention-deficit hyperactivity disorder medication, sildenafil and novel psychoactive substances (also known as 'legal highs'), tend to be used by younger, relatively well educated and employed males, who thus may be at increased risk of developing serotonin syndrome. Those who combine ecstasy with antidepressants more often report potentially serious symptoms such as muscle rigidity and nystagmus compared with those who use ecstasy alone (Copeland 2006). Several cases of serotonin syndrome following combined overdose with ecstasy and unprescribed moclobemide have been reported; in the more severe of these cases the person developed sudden onset of hypoxia associated with bronchospasm secondary to the rigidity of respiratory muscles (Silins 2007).

### *Serotonin syndrome and headache*

Serotonin is thought to modulate headache via specific receptor subtypes; many serotonergic medications have also been associated with headache as a side-effect (Ferrari 2006). A recent case series of four patients thought to have serotonin syndrome associated with fluoxetine, paroxetine and tramadol use reported headache as a prominent presenting feature (Prakash 2014).

Since 2006, the US Food and Drug Administration (FDA) has alerted healthcare professionals of the 'potential for life-threatening serotonin syndrome' in patients taking serotonergic medications (specifically SSRIs or serotonin-noradrenaline reuptake inhibitors – SNRIs – who are co-prescribed triptans for migraine headaches (FDA 2006). However, the clinical evidence underpinning the FDA's warning has been questioned (Evans 2010). Further, triptans are selective agonists at 5-HT<sub>1B/1D/1F</sub> receptor subtypes, with a much weaker affinity at 1A receptors and not thought to possess agonist activity at 2A receptors; there is thus also a view that triptans lack a plausible pharmacological role in precipitating or contributing to the severe

toxicity observed in serotonin syndrome (Gillman 2010a). Nevertheless, the FDA has maintained its stance; there is general consensus that patient advice, caution and close monitoring are warranted (Evans 2010).

### **Serotonin syndrome and interface with other specialties**

Serotonin syndrome has been reported peri-operatively as a result of serotonergic potentiation secondary to the coadministration of fentanyl during anaesthesia (Gillman 2005), to the use of methylene blue dye during parathyroid surgery (Gillman 2010b) and to the use of linezolid in the treatment of severe infection (Shaikh 2011). Linezolid is a synthetic oxazolidinone antibiotic with a half-life of 5 h; it was originally developed for use as an antidepressant owing to its reversible non-selective MAO inhibitory properties. Its coincidental antimicrobial properties led to its further development and subsequent use in treating specific Gram-positive infections such as methicillin-resistant *Staphylococcus aureus* (MRSA) (Jones 2004). Serotonin syndrome has recently been described following rewarming in patients who had been treated with therapeutic hypothermia for cardiac arrest (Fugate 2014) and in a breastfed neonate whose mother had been taking 60 mg fluoxetine daily (Morris 2015).

### **Management of serotonin syndrome**

Treatment in mild to moderate cases consists of identifying and discontinuing the serotonergic medication(s), whereupon resolution usually follows within 1–3 days. There is currently no specific test to confirm the diagnosis of serotonin syndrome. Non-specific abnormalities, including raised white cell count, raised creatine kinase, and reduced magnesium, calcium and sodium levels, have been noted. However, monitoring of haematological and biochemical parameters, including a drug screen, may be useful where the diagnosis is unclear and in the treatment of patients who exhibit severe toxicity (Iqbal 2012). Maintain fluid balance, paying careful attention to urinary output and undertake regular observations of pulse, blood pressure and temperature (Buckley 2014).

An electrocardiogram (ECG) should be undertaken, for example where tricyclic antidepressants have been ingested; arrhythmias and postural hypotension may not be self-evident. Liver toxicity may ensue either directly from large doses of lofepramine or as a secondary effect of the serotonin syndrome. An electroencephalogram may help in excluding non-convulsive epileptic states. Care should be taken where slow-release preparations or

benzodiazepines have been ingested: observation times should be increased to 12 h or more in order to monitor for a delay in emergent side-effects. This should not detract from managing the patient's immediate presenting symptoms in the meantime. Measurement of urinary dopamine and serotonin metabolites has been proposed as a possible adjunct to clinical assessment.

In moderate to severe serotonin syndrome individuals are likely to exhibit a degree of agitation and this can be treated with oral diazepam. However, it is important not to underestimate the possibility of rapid deterioration, especially in situations where even low doses of both an MAOI and an SSRI have been taken together, and input from the medical team should be sought. This should be done immediately if the patient has consumed large quantities of drugs, if there is doubt about the quantity or type of medication ingested, if novel psychoactive substances have been used, if combinations of medications have been taken or if there is suicidal intent with an unknown quantity of medication. There may also be cardiotoxic effects, such as prolonged QT interval, as in the case of overdose with citalopram. Norfluoxetine has a half-life of about 17 days, while its parent compound fluoxetine has a half-life of about 7 days. Together, the two compounds can precipitate serotonin syndrome several weeks after the last dose, especially if an irreversible MAOI is subsequently prescribed.

Drug screening should be undertaken and early contact with toxicology services considered. Benzodiazepines may help with muscle rigidity/hyperactivity, myoclonus, seizures and agitation. Lorazepam or oxazepam have been suggested as the most appropriate benzodiazepine, the rationale being their shorter duration of action and lack of active metabolites (Ahuja 2009). Diazepam use has also been described (Buckley 2014). Prudence is required in the use of benzodiazepines in elderly patients, who may develop delirium or hypotension, especially where there is impaired liver or kidney function.

Common antipyretic drugs are not indicated in serotonin syndrome. Excess muscle activity contributes to the hyperthermia, so muscle paralysis may be required to curb this in extreme cases (Boyer 2005; Volpie-Abadie 2013). Avoid the use of restraint, as active resistance can contribute to metabolic acidosis and lead to further rise in body temperature. Pyrexia of 38.5°C or higher, and/or markedly increased truncal rigidity may herald imminent respiratory distress: in such cases senior medical advice should be sought immediately, as rapid deterioration is likely to ensue (Dunkley 2003).

Further interventions include the antihistamine cyproheptadine (an antagonist at both 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors) and chlorpromazine, a 5-HT<sub>2A</sub> antagonist which may require prior fluid loading to prevent hypotension (Buckley 2014). Although both these drugs have recognised serotonin receptor antagonist properties, their use has been described on a theoretical basis only and they remain unlicensed for this purpose. Owing to the common symptom profile shared by serotonin syndrome and neuroleptic malignant syndrome, it may be prudent to confine the use of chlorpromazine to severe cases treated by experienced prescribers of the drug. There is a lack of supporting evidence for the use of propranolol or haloperidol in serotonin syndrome.

Highly toxic states, where the body temperature rises to over 40°C, are associated with a risk of multi-organ failure and death; active cooling is imperative (Buckley 2014). It has been suggested that lowering of body temperature reduces functionality of the 5-HT<sub>2A</sub> receptors (Krishnamoorthy 2010), which may minimise triggering of neurotoxic cascades (Fugate 2014). Rapid cooling may be achieved by covering the body in ice packs in conjunction with the use of cooled fluids for bladder and/or peritoneal lavage and for intravenous administration. Disseminated intravascular coagulation, kidney failure, acidosis and acute respiratory distress syndrome are also possible secondary complications of severe serotonin syndrome and intensive supportive care is likely to be necessary.

### Further management

A detailed review of the patient's prescribed drugs should be undertaken 1–2 weeks after the serotonin syndrome has resolved. Alternatives should be considered where possible. Some of the causative medications may be individually retitrated, beginning at lower doses. Most SSRIs have a half-life of 12–36 h and require a washout period of 7–14 days before restarting. Where an MAOI was involved in the cause of serotonin syndrome, serotonergic agents should not be restarted for at least 14 days. Fluoxetine has active metabolites with a 5–7 day half-life, thereby requiring a 5-week washout period; serotonergic interactions may thus occur several weeks after its discontinuation. Patients should be monitored for increased anxiety, agitation, tremor, pulse, blood pressure, temperature, headache and reflexes. Care should be exercised; recurrence of serotonin syndrome following exposure to a different serotonergic drug has been described in the presence of pre-existing liver disease (Tomaselli 2004).

## Prognosis

The prognosis is good, especially where there has been early recognition, immediate discontinuation of the causal medication and rapid establishment of appropriate supportive measures (Sun-Edelstein 2008). A degree of confusion may persist for a few days, and sometimes muscle pain for longer. Chechani (2002) reported four severe episodes of serotonin syndrome in the same woman; with two different SSRIs, she continued to experience muscle aches and tremors 2 months after resolution of the syndrome. This may be partly due to the necessity of abrupt cessation of potent CYP2D6 inhibitors such as paroxetine, or occasionally to SSRI-induced extrapyramidal side-effects of medications with long half-lives, such as fluoxetine, along with their active metabolites (Lane 1998).

## Prevention

We have an aging population often treated with complex regimens of multiple drugs. This poses particular challenges if several medical conditions co-occur. Lingam & Scott (2002) state that 10–60% of patients do not take their antidepressant medication as prescribed; introduction of the SSRIs appears to have had little impact on this. Patterns of adherence to prescribed antidepressants vary from taking excessive amounts sporadically, to periodic use, to frequent stop–starts, to abrupt cessation; around a third of patients who discontinue their medication may not reveal this to their doctor. There is thus not only the risk of toxicity but of experiencing discontinuation symptoms, which include sleep disturbance, agitation, anxiety and depression (Demyttenaere 2000). Patient- and/or illness-related factors may contribute to this; sensitively exploring patients' attitudes, associated health beliefs and treatment expectations may be helpful in assessing the degree of medication adherence. Routine enquiry about various foods, including caffeine consumption, and the use of recreational drugs may assist in the face of apparent treatment non-response before prescribing second- or even third-line medication. The importance of advising patients against mixing other substances with prescribed drugs should not be underestimated. Medication reconciliation and communication with other people who may be prescribing for patients are key.

## Acknowledgement

I wish to thank Dr Mark Hugson, consultant psychiatrist (retired), and Mr Paul Davies, prescribing management pharmacist with Mental Health Services – NHS Greater Glasgow

and Clyde, for their encouraging scrutiny of the draft manuscript.

## References

- Ahuja N, Cole AJ (2009) Hyperthermia syndromes in psychiatry. *Advances in Psychiatric Treatment*, **15**: 181–91.
- Boyer E, Shannon M (2005) The serotonin syndrome. *New England Journal of Medicine*, **352**: 1112–20.
- Buckley AB, Dawson AH, Isbister GK (2014) Serotonin syndrome. *BMJ*, **348**: g1626.
- Cauli O, Morelli M (2005) Caffeine and the dopaminergic system. *Behavioural Pharmacology*, **16**: 63–77.
- Chander WP, Singh N, Mukhiya GK (2011) Serotonin syndrome in maintenance haemodialysis patients following sertraline treatment for depression. *Journal of the Indian Medical Association*, **109**: 36–7.
- Chang TW, Castle DJ (2004) Layer upon layer, thermoregulation in schizophrenia. *Schizophrenia Research*, **69**: 149–57.
- Chechani V (2002) Serotonin syndrome presenting as hypotonic coma and apnoea: potentially fatal complications of selective serotonin reuptake inhibitor therapy. *Critical Care Medicine*, **30**: 473–6.
- Cooper BE, Sejnowski CA (2013) Serotonin syndrome: recognition and treatment. *AACN Advanced Critical Care*, **24**: 15–20.
- Copeland J, Dillon P, Gascoigne M (2006) Ecstasy and the concomitant use of pharmaceuticals. *Addictive Behaviors*, **31**: 367–70.
- Demyttenaere K, Haddad P (2000) Compliance with antidepressant therapy and antidepressant discontinuation symptoms. *Acta Psychiatrica Scandinavica Supplementum*, **403**: 50–6.
- Dunkley EJC, Isbister GK, Sibbritt D, et al (2003) The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. *QJM*, **96**: 635–42.
- Ener RA, Sharon B, Meglathery MD, et al (2003) Serotonin syndrome and other serotonergic disorders. *Pain Medicine*, **4**: 63–74.
- Evans RW, Tepper SJ, Shapiro RE, et al (2010) The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin–norepinephrine reuptake inhibitors: American Headache Society position paper. *Headache*, **50**: 1089–99.
- Ferrari A (2006) Headache: one of the most common and troublesome adverse reactions to drugs. *Current Drug Safety*, **1**: 34–58.
- Food and Drug Administration (2006) Public health advisory – combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. FDA (<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124349.htm>). Page last updated 16 Aug 2013.
- Fox MA, Jensen CL, Gallagher PS, et al (2007) Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. *Neuropharmacology*, **53**: 643–56.
- Fugate JE, White RD, Rabinstein AA (2014) Serotonin syndrome after therapeutic hypothermia for cardiac arrest: a case series. *Resuscitation*, **85**: 774–7.
- Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *British Journal of Anaesthesia*, **95**: 434–41.
- Gillman PK (2010a) Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. *Headache*, **50**: 264–72.
- Gillman PK (2010b) CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. *Journal of Psychopharmacology*, **25**: 429–36.
- Haddad PM, Dursun SM (2008) Neurological complications of psychiatric drugs: clinical features and management. *Human Psychopharmacology: Clinical and Experimental*, **23**: 15–26.
- Hegerl U, Bottlender R, Gallinat J, et al (1998) The serotonin syndrome scale: first results on validity. *European Archives of Psychiatry and Clinical Neuroscience*, **248**: 96–103.

### MCQ answers

1 d 2 c 3 b 4 d 5 a

Herraz T, Chapparo C (2006) Human monoamine oxidase inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. *Life Sciences*, **78**: 795–802.

Iqbal MM, Miles JB, Kaplan J, et al (2012) Overview of serotonin syndrome. *Annals of Clinical Psychiatry*, **24**: 310–18.

Isbister IK, Buckley NA, Whyte IM (2007) Serotonin toxicity: a practical guide to diagnosis and treatment. *Medical Journal of Australia*, **187**: 361–5.

Jacobs BL (1974) Effect of two dopamine receptor blockers on a serotonin-mediated behavioural syndrome in rats. *European Journal of Pharmacology*, **27**: 363–6.

Jones SL, Athan E, O'Brien D (2004) Serotonin syndrome due to co-administration of linezolid and venlafaxine. *Journal of Antimicrobial Chemotherapy*, **54**: 289–90.

Kiani J, Imam SZ (2007) Medicinal importance of grapefruit juice and its interactions with various drugs. *Nutrition Journal*, **6**: 33.

Krishnamoorthy S, Ma Z, Zhang G, et al (2010) Involvement of 5-HT<sub>2A</sub> receptors in the serotonin syndrome caused by excessive 5-HT efflux in the rat brain. *Clinical Pharmacology and Toxicology*, **107**: 830–41.

Lane RM (1998) SSRI-induced extra-pyramidal side effects and akathisia: implications for treatment. *Journal of Psychopharmacology*, **12**: 192–214.

Lee AJ, Chan WK, Harralson AF, et al (1999) The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. *Clinical Therapeutics*, **21**: 1890–9.

Lee YC, Chen PP (2010) A review of SSRIs and SNRIs in neuropathic pain. *Expert Opinion on Pharmacotherapy*, **11**: 2813–25.

Lingam R, Scott J (2002) Treatment non-adherence in affective disorders. *Acta Psychiatrica Scandinavica*, **105**: 164–72.

Lynch T, Price A (2007) The effect of cytochrome P450 metabolism on drug response, interactions and adverse effects. *American Family Physician*, **76**: 391–6.

Monte A, Chuang R, Bodmer M (2010) Dextromethorphan, chlorpheniramine and serotonin toxicity: case report and systemic literature review. *British Journal of Clinical Pharmacology*, **70**: 794–8.

Morris R, Matthes J (2015) Serotonin syndrome in a breast-fed neonate. *BMJ Case Reports*, doi: 10.1136/bcr-2015-209418 (published online 6 May).

Morrish PK (2014) Serotonin syndrome. *BMJ*, **348**: g1626.

Odagaki Y (2009) Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? *Current Drug Safety*, **4**: 84–93.

Okamoto N, Sakamoto K, Yamada M (2012) Transient serotonin syndrome by concurrent use of electroconvulsive therapy and selective serotonin reuptake inhibitor: a case report and review of the literature. *Case Reports in Psychiatry*, **2012**: article ID 215214.

Park SH, Wackermah RC, Stimmel GL (2014) Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? *Journal of Pharmacy Practice*, **27**: 71–8.

Prakash S, Belani P, Trivedi A (2014) Headache as a presenting feature in patients with serotonin syndrome: a case series. *Cephalalgia*, **34**: 148–53.

Radomski JW, Dursun SM, Reveley MA, et al (1999) An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. *Medical Hypotheses*, **55**: 218–24.

Shaikh Z, Krueper S, Malins T (2011) Serotonin syndrome: take a close look at the unwell surgical patient. *Annals of The Royal College of Surgeons of England*, **93**: 569–72.

Shee JC (1960) Dangerous potentiation of pethidine by iproniazid and its treatment. *BMJ*, **2**: 507–9.

Shioda K, Nisijima K, Nishida S, et al (2004) Possible serotonin syndrome arising from an interaction between caffeine and serotonergic antidepressants. *Human Psychopharmacology: Clinical and Experimental*, **19**: 353–4.

Silins E, Copeland J, Dillon P (2007) Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. *Australian & New Zealand Journal of Psychiatry*, **41**: 649–55.

Steele D, Keltner NL, McGuinness TM (2011) Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome? *Perspectives in Psychiatric Care*, **47**: 58–62.

Sternbach H (1991) The serotonin syndrome. *American Journal of Psychiatry*, **148**: 705–13.

Sun-Edelstein C, Tepper SJ, Shapiro RE (2008) Drug-induced serotonin syndrome: a review. *Expert Opinion on Drug Safety*, **7**: 587–96.

Tomaselli G, Modestin J (2004) Repetition of serotonin syndrome after re-exposure to SSRI: a case report. *Journal of Pharmacopsychiatry*, **37**: 236–8.

Volpie-Abadie J, Kaye A, Kaye D (2013) Serotonin syndrome. *Ochsner Journal*, **13**: 533–40.

Zhou S, Chan E, Pan SQ (2004) Pharmacokinetic interactions of drugs with St John's Wort. *Journal of Psychopharmacology*, **18**: 262–76.

Zhou SF (2009) Polymorphisms of human cytochrome P450 2D6 and its clinical significance: Part 1. *Clinical Pharmacokinetics*, **48**: 689–723.

**MCQs**

Select the single best option for each question stem

**1 How many families of serotonin receptor subtype have been identified?**

- a 3
- b 9
- c 2
- d 7
- e 5.

**2 Which body organ contains the highest density of the cytochrome P450 enzymes?**

- a lungs
- b spleen
- c liver
- d kidneys
- e brain.

**3 Caffeine is both metabolised by and an inhibitor of which CYP enzyme?**

- a CYP2D6
- b CYP1A2
- c CYP2C19
- d CYP2C9
- e CYP3A4.

**4 Which of the following was noted in severely toxic presentations of serotonin syndrome and added to the Hunter criteria?**

- a tremor
- b diaphoresis
- c hyperreflexia
- d rigidity
- e agitation.

**5 Which treatment option has not been found to be useful in the clinical management of serotonin syndrome?**

- a antipyretic medication
- b discontinuation of serotonergic medication
- c chlorpromazine
- d benzodiazepines
- e cyproheptadine.